Liquid Biopsy for MPNST Detection via cfDNA Fragment Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting malignant peripheral nerve sheath tumors (MPNST) in Neurofibromatosis Type 1 patients are inadequate due to difficulties in distinguishing between MPNST and its benign precursor, leading to delayed diagnosis and ineffective treatment, as existing imaging and biopsy techniques lack sensitivity and specificity.
Innovation Solution
The use of ultra-low-pass whole genome sequencing (ULP-WGS) on cell-free DNA from plasma samples to analyze read fragment size distribution and copy number alterations, enabling early detection and monitoring of MPNST by differentiating it from benign plexiform neurofibroma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If imaging techniques are used to detect MPNST, then non-invasive monitoring is achieved, but the ability to distinguish MPNST from benign plexiform neurofibroma is insufficient
Solution Approach 1:
The patent introduces cell-free DNA (cfDNA) as an intermediary biomarker to indirectly detect MPNST. Instead of directly imaging the tumor, the method sequences cfDNA fragments released into plasma by tumor cells, using fragment size distribution (enriched for shorter fragments in MPNST) and copy number alterations as mediators to distinguish malignant from benign lesions with high specificity.
Solution Approach 2:
The patent replaces mechanical/invasive biopsy procedures with a molecular-based liquid biopsy approach. Instead of physically extracting and examining tissue samples, the method uses ultra-low-pass whole genome sequencing of plasma cfDNA to detect MPNST through biochemical signatures (fragment size and copy number patterns), eliminating the need for invasive tissue sampling.
2Measurement precision
If biopsy is performed to diagnose MPNST, then direct tissue analysis is achieved, but sampling errors occur due to intralesional heterogeneity
Solution Approach 1:
The patent extracts and analyzes cell-free DNA fragments that are released into the circulation by tumor cells. By sequencing cfDNA from plasma, the method captures genetic information from the entire tumor burden without needing to physically sample the tumor tissue, thereby avoiding sampling errors caused by intralesional heterogeneity while maintaining diagnostic accuracy.
3Reliability
If complete excision of plexiform neurofibroma is performed, then definitive treatment is achieved, but morbid procedures are required
Solution Approach 1:
The patent performs preliminary detection and monitoring of MPNST transformation using liquid biopsy before complete surgical excision becomes necessary. By detecting MPNST early through cfDNA analysis and monitoring treatment response serially, the method enables less invasive management strategies and avoids morbid complete excisions when less aggressive approaches suffice.
4Reliability
If serial biopsies are performed to monitor MPNST, then continuous surveillance is achieved, but the procedure becomes impractical due to multiple lesions
Solution Approach 1:
The patent creates a universal monitoring method that detects MPNST transformation from any plexiform neurofibroma lesion through a single plasma sample. The liquid biopsy approach simultaneously surveils all tumor sites systemically, eliminating the need for multiple individual biopsies of different lesions while maintaining comprehensive monitoring sensitivity through cfDNA analysis.
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of methods for detecting cancer in Neurofibromatosis Type 1 (NF1) patients.